Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.
Michael Edward JohnstonMaria Prates RivasDelphine NicolleAurore GorseRuhi GulatiMeenasri KumbajiMatthew T WeirauchAlexander BondocStefano CairoJames GellerGregory TiaoNikolai TimchenkoPublished in: Hepatology (Baltimore, Md.) (2021)
In this study, we showed that aggressive HBL is moderated by ALCDs, which are activated by the ph-S6-p53/PARP1 pathway. By using the PARP1 inhibitor Ola, we suppressed tumor growth in HBL-PDX models, which demonstrated its utility in future clinical models.
Keyphrases